A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

NCT00964704 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No patients have been recruited therefore study has been cancelled

Conditions

Breast Cancer

Interventions

DRUG: bevacizumab [Avastin]
DRUG: capecitabine [Xeloda]
DRUG: docetaxel
DRUG: trastuzumab [Herceptin]

Sponsor

Hoffmann-La Roche